相关实验视频
Updated: Sep 12, 2025

04:27
Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
5.7K
在极度早产的婴儿中,用于支气管肺功能障碍症的产后全身性皮质类固醇治疗以呼吸系统严重度评分为指导
Gyeong Eun Yeom1, Ju Sun Heo1,2, Baek Sup Shin1
1Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea.
Clinical and experimental pediatrics
|August 8, 2025
概括
针对极度早产 (EP) 婴儿的新呼吸系统严重性评分 (RSS) 引导的方案减少了严重的支气管肺功能障碍 (BPD),但没有影响神经发育结果. 这种有针对性的方法完善了对脆弱新生儿的类固醇治疗.
科学领域:
- 新生儿医学 新生儿医学
- 儿科肺病学 儿科肺病学
- 临床试验方法论 临床试验方法论
背景情况:
- 支气管肺功能障碍症 (BPD) 是极度早产 (EP) 婴儿的一个重大并发症.
- 产后系统性皮质类固醇用于管理BPD,但引起了人们对神经发育结果的担忧.
- 对BPD进行类固醇治疗的最佳时间和标准尚不清楚.
研究的目的:
- 为了评估呼吸系统严重性评分 (RSS) 引导的产后全身皮质类固醇协议.
- 评估本协议对机械通风EP婴儿BPD严重程度和神经发育结果的影响.
主要方法:
- 一项历史性比较研究,比较了协议实施前后的情况 (2010-2014年与2016-2022年).
- 纳入标准:怀孕28周以下的婴儿,在出生后的第14天接受呼吸.
- 该协议使用RSS指导皮质类固醇的启动;比较了BPD严重程度和神经发育障碍 (NDI).
主要成果:
- 后协议组显示德克萨米他的使用增加和早期启动.
- 在后协议组中,詹森0级BPD显著增加,特别是在接受非类固醇治疗的婴儿中.
- 在后协议组中,接受类固醇治疗的婴儿的严重BPD (3级) 减少,轻度BPD (1级) 增加.
- 两组之间死亡率或严重神经发育障碍没有显著差异.
结论:
- 该RSS指导的协议有助于有针对性和早期的类固醇管理.
- 这种策略有效地减少严重的BPD,而不会对神经发育产生不良影响.
- 这种以RSS为指导的方法为EP婴儿的产后皮质类固醇治疗提供了一个精细的策略.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
312
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
312
Acute Respiratory Failure-V
208
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
208
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
394
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
394
Acute Respiratory Failure-II
363
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
363
Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K

